ALAMEDA, Calif.--(BUSINESS WIRE)--Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today outlined development progress toward commercializing, as early as 2016, an ultrasensitive immunoassay system for the in vitro diagnostics (IVD) market.
Help employers find you! Check out all the jobs and post your resume.
